Evidence map›Paper›PMID 40065365›Full record

ArticleJournal of translational medicine2025

Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer.

Enkui Zhang, Yongsu Ma, Zonghao Liu, Jixin Zhang, Weikang Liu, Yiran Chen, Guangnian Liu, Xinxin Liu, Fusheng Zhang, Yu Zhu and 2 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Enkui Zhang *Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yongsu Ma *Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Zonghao LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Jixin ZhangDepartment of Pathology, Peking University First Hospital, Beijing, 100034, China.
Weikang LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yiran ChenDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Guangnian LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Xinxin LiuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Fusheng ZhangDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yu ZhuDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Yinmo YangDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China. YangyinmoSCI@bjmu.edu.cn.
Xiaodong TianDepartment of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, China. tianxiaodong@pkufh.com.

Funding

Beijing Natural Science Foundation L246015Interdepartmental Research Project of Peking University First Hospital 2023IR23Interdepartmental Research Project of Peking University First Hospital 2024IR11National Key Research and Development Program of China 2021YFA0909900National Key Research and Development Program of China 2023YFC2413400National Natural Science Foundation of China 82171722National Natural Science Foundation of China 82271764National Natural Science Foundation of China 82471772Research and Translational Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital Z221100007422070Scientific Research Seed Fund of Peking University First Hospital 2023SF47Youth Clinical Research Project of Peking University First Hospital 2023YC06
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is among the most aggressive cancers, with rising incidence and limited responsiveness to immunotherapy due to its highly suppressive tumor microenvironment (TME). Tertiary lymphoid structures (TLS), ectopic formation structures of immune cells, are linked to better prognosis and improved immunotherapy responses in PDAC. Understanding TLS's role in PDAC could enhance immunotherapy effectiveness.

methodsThis study integrated transcriptomic and clinical data from 310 PDAC patients in GEO database. We performed consensus clustering using tumor-associated TLS (TA-TLS) genes, identifying three distinct molecular subtypes. Single-sample gene set enrichment analysis (ssGSEA) was then employed to calculate a TLS score for each patient, allowing for TLS-based evaluation. Key prognostic genes were identified using an iterative LASSO method, leading to the construction of a risk assessment model, which was validated across independent cohorts. We further analyzed the TLS score using single-cell RNA sequencing (scRNA-seq), visualized key gene expression, and validated protein expression through immunohistochemistry (IHC). Additionally, we explored the effects of DNASE1L3 on cell proliferation and migration, and its immune-related functions using Gene Set Enrichment Analysis (GSEA) and multiplex cytokine analysis.

resultsConsensus clustering revealed three PDAC molecular subtypes with significant differences in prognosis, TA-TLS gene expression, and TME features. The TLS score effectively stratified patients into high and low groups, correlating with survival outcomes and TME characteristics. Our risk model, validated across cohorts, reliably predicted patient outcomes. Validation studies showed lower expression of DNASE1L3 and IL33 in tumor tissues. scRNA-seq confirmed TLS score associations with immune cells. DNASE1L3 overexpression inhibited PDAC cell proliferation and migration, with cytokine analysis indicating increased immune activity.

conclusionsThis study elucidated the expression profile of TA-TLS genes in PDAC, constructed a TLS gene-based scoring system, and developed a related risk model. We also explored the functions and potential antitumor mechanisms of key genes, providing evidence and new insights for enhancing TLS-targeted immunotherapy strategies in PDAC.

Indexed as

Pancreatic NeoplasmsTertiary Lymphoid StructuresCarcinoma, Pancreatic DuctalCell Line, TumorCell MovementCell ProliferationCluster AnalysisFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentCharacterizationPancreatic cancerPrognostic signatureTertiary lymphoid structuresTumor microenvironment

Identifiers

PMID40065365
PMCPMC11892293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.